Diabetes therapy - Akesis Pharmaceuticals

Drug Profile

Diabetes therapy - Akesis Pharmaceuticals

Alternative Names: AKP-320

Latest Information Update: 20 Apr 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akesis Pharmaceuticals
  • Class Chromium compounds; Vanadium compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Feb 2009 Discontinued - Clinical-Phase-Unknown for Type-2 diabetes mellitus in USA (PO)
  • 15 May 2006 Akesis and Profil Institute for Clinical Research have signed a consulting agreement for clinical trials in type 2 diabetes
  • 14 Feb 2005 Clinical trials in Diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top